SRRA - Sierra Oncology, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.76
-0.08 (-2.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.84
Open2.82
Bid2.66 x 1000
Ask3.01 x 1800
Day's Range2.56 - 2.85
52 Week Range1.21 - 4.09
Volume613,120
Avg. Volume513,998
Market Cap205.1M
Beta2.51
PE Ratio (TTM)N/A
EPS (TTM)-0.84
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.83
Trade prices are not sourced from all markets
  • ACCESSWIRE21 days ago

    Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.

  • Can The Uptrend Continue for Sierra Oncology (SRRA)?
    Zacks2 months ago

    Can The Uptrend Continue for Sierra Oncology (SRRA)?

    Investors certainly have to be happy with Sierra Oncology, Inc. (SRRA) and its short term performance

  • ACCESSWIRE2 months ago

    Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).

  • Associated Press2 months ago

    Sierra Oncology, Inc: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 19 cents. The company's shares closed at $1.97. A year ago, they were trading at $1.25. _____ This story was generated ...

  • CNW Group2 months ago

    Sierra Oncology Reports First Quarter Results

    Sierra Oncology Reports First Quarter Results

  • CNW Group3 months ago

    Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

    Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

  • CNW Group4 months ago

    Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

    Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

  • PR Newswire4 months ago

    Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

    VANCOUVER, March 19, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that Dr. Angie You, Chief Business & Strategy Officer, Head of Commercial, will present an overview of the company at the Future Leaders in the Biotech Industry Conference being held in New York. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com. Sierra Oncology is a clinical stage drug development company advancing next generation DDR therapeutics for the treatment of patients with cancer.

  • CNW Group4 months ago

    Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

    Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

  • PR Newswire4 months ago

    Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

    VANCOUVER , March 14, 2018 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for ...

  • PR Newswire4 months ago

    Sierra Oncology Announces Pricing of Public Offering of Common Stock

    VANCOUVER, March 2, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 19,000,000 shares of its common stock at a price of $2.25 per share, with expected gross proceeds to Sierra Oncology of $42,750,000. In addition, Sierra Oncology has granted the underwriters a 30-day option to purchase up to 2,850,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Sierra Oncology intends to use the net proceeds from the public offering to fund development of its product candidates, SRA737 and SRA141, as well as for general corporate purposes.

  • CNW Group4 months ago

    Sierra Oncology Announces Pricing of Public Offering of Common Stock

    Sierra Oncology Announces Pricing of Public Offering of Common Stock

  • PR Newswire5 months ago

    Sierra Oncology Announces Proposed Public Offering of Common Stock

    VANCOUVER, March 1, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Sierra Oncology. In addition, Sierra Oncology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

  • CNW Group5 months ago

    Sierra Oncology Announces Proposed Public Offering of Common Stock

    Sierra Oncology Announces Proposed Public Offering of Common Stock

  • 5 Biotech Stocks to Sell Amid the Latest Slaughter
    InvestorPlace5 months ago

    5 Biotech Stocks to Sell Amid the Latest Slaughter

    Stocks are under fresh pressure after new Federal Reserve chairman Jerome Powell sounded a hawkish note in his first appearance before Congress this week. The odds of four quarter-point rate hikes is now rising fast, pressuring long-term Treasury yields higher, bringing back the headwind that pushed stocks into a correction earlier this month.

  • PR Newswire5 months ago

    Sierra Oncology Reports 2017 Year End Results

    - Janssen supply agreement for ZEJULA® (niraparib) facilitates novel PARPi combination trial with SRA737 in prostate cancer - - SRA737 clinical development program significantly expanded - - SRA737 clinical ...

  • CNW Group5 months ago

    Sierra Oncology Reports 2017 Year End Results

    Sierra Oncology Reports 2017 Year End Results

  • PR Newswire5 months ago

    Sierra Oncology Significantly Expands Clinical Development Program

    VANCOUVER, Feb. 27, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today reported significant progress in the advancement of its strategic pipeline of drug assets. The company announced noteworthy progress in the Dose Escalation Phase 1 portions for both of its ongoing Phase 1/2 clinical trials evaluating its potential best-in-class Chk1 inhibitor, SRA737.

  • CNW Group5 months ago

    Sierra Oncology Significantly Expands Clinical Development Program

    Sierra Oncology Significantly Expands Clinical Development Program

  • PR Newswire5 months ago

    Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

    VANCOUVER, Feb. 27, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced the signing of a clinical supply agreement with Janssen Research & Development, LLC. (Janssen) for access to TESARO's ZEJULA® (niraparib), an orally administered poly (ADP-ribose) polymerase (PARP) inhibitor undergoing clinical development by Janssen for patients with prostate cancer. Sierra intends to evaluate its Chk1 inhibitor, SRA737, in combination with niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

  • CNW Group5 months ago

    Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

    Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

  • CNW Group5 months ago

    Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

    Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

  • PR Newswire5 months ago

    Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

    VANCOUVER, Feb. 21, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced it has been accepted to present preclinical data demonstrating that its Chk1 inhibitor, SRA737, synergizes with niraparib, a poly ADP-ribose inhibitor (PARPi), in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2018 being held in Chicago, Illinois from April 14-18. Notably, this combination was effective in homologous repair proficient tumor cell lines where PARP inhibitors are substantially less active in the clinical setting," said Dr. Christian Hassig, Chief Scientific Officer of Sierra Oncology.

  • CNW Group5 months ago

    Sierra Oncology to host Program Update in New York on February 27th

    Sierra Oncology to host Program Update in New York on February 27th

  • PR Newswire5 months ago

    Sierra Oncology to host Program Update in New York on February 27th

    VANCOUVER, Feb. 6, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced it will host a Program Update on Tuesday, February 27th from 10:00 a.m. – 12:00 p.m. Eastern Time (ET) at the Lotte New York Palace in New York, NY. The company will be joined by Dr. Udai Banerji, Chief Investigator for Sierra's ongoing SRA737 Phase 1/2 clinical studies, and Dr. Alan D'Andrea, a member of Sierra's DDR Advisory Committee.